Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Prognostic Value of Insulin Resistance and Hyperglycemia Biomarkers for Long-term Risks of Cardiometabolic Outcomes

Prognostic value of insulin resistance and hyperglycemia biomarkers for long-term risks of cardiometabolic outcomes

Authors: Rooney MR, Daya NR, Leong A, McPhaul MJ, Shiffman D, Meigs JB, Selvin E.

Citation: J Diabetes Complications. 2023 Aug 2;37(9):108583. doi:10.1016/j.jdiacomp.2023.108583. Online ahead of print.

Specialties: Cardiology, Endocrinology

Related content

Publication
The relationship between insulin resistance and ion mobility lipoprotein fractions
Test FAQ
Insulin Intact LC MS MS
Test FAQ
CardioIQ® Insulin Resistance Panel with Score
Publication
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
Publication
An Insulin Resistance Score Improved Diabetes Risk Assessment in the Malmö Prevention Project-A Longitudinal Population-Based Study of Older European

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.